> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Luna Health raises $23.6M for automated insulin delivery solution
- URL: https://med-techinsights.com/luna-health-raises-series-a-for-automated-insulin-delivery-solution/
- Published: 2025-08-21T13:20:39.000Z
- Updated: 2026-10-22T08:31:54.000Z
- Description: Luna Health Inc., a medical device company pioneering a first-of-its-kind method of insulin delivery for insulin pen users, has announced the closing of its 23.6 million USD Series A financing led by Vensana Capital, with participation from the Swiss Diabetes Venture Fund, Ascensia Diabetes Care, Wi
- Author: Oliver Johnson
- Tags: Medical Device Manufacturing, News

[**Luna Health Inc.**,](https://pr.report/dese?ref=med-techinsights.com) a medical device company pioneering a first-of-its-kind method of insulin delivery for insulin pen users, has announced the closing of its 23.6 million USD Series A financing led by Vensana Capital, with participation from the Swiss Diabetes Venture Fund, Ascensia Diabetes Care, Winklevoss Capital, and other prominent investors with deep expertise in diabetes technology and value creation.

The funding will accelerate development of Luna, the ‘world’s smallest’ insulin patch pump paired with the firm’s fully closed-loop insulin dosing algorithm, created to serve the vast majority of people with Type 2 Diabetes (T2D) and Type 1 Diabetes (T1D) who rely on insulin pens.

Luna’s first-in-class, low-profile, iCGM-compatible, low-cost patch pump delivers automated doses of rapid-acting insulin during sleep, when over 80% of the glucose improvement from traditional pump-based automated insulin delivery happens, without requiring people with diabetes to make the leap to full-time pump therapy.

By focusing on where automation has the greatest impact on glucose control, Luna dramatically reduces complexity, lowers costs, and reduces barriers to adoption, thereby making automated insulin delivery accessible to millions of people worldwide who are either unwilling or unable to wear a traditional pump 24/7.

“We are incredibly excited and fortunate to partner with Vensana Capital to accelerate bringing to market our products that solve the single largest problem in all of diabetes – nighttime glucose control for pen users,” added Jon Brilliant, co-founder and CFO of Luna. “Vensana’s track record and leadership in the medical device ecosystem further bolsters the world-class team of employees and advisors that we have assembled to tackle this problem.”

“Luna is solving a challenge the diabetes field has struggled with for decades-bringing the benefits of automation to injection users,” said Justin Klein, MD, JD, co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. “Luna’s platform has the potential to fundamentally expand the reach of automated insulin delivery and drive measurable improvements in outcomes for people with both Type 1 and Type 2 diabetes.”

The company will use the Series A funding to advance regulatory submissions, conduct clinical studies, build manufacturing capacity, and expand clinical and market access programs — all to make automated insulin delivery much more accessible to people with diabetes.